Amsterdam and Irvine, California (ots/PRNewswire) - - Not for release, distribution or publication in whole or in part, directly or indirectly, into or in the United States, Australia, Canada, OR Japan Agendia (or the "Company"), a commercial-stage molecular cancer diagnostics company, announces the postponement of its Initial Public Offering ("IPO") that was due to price today. Agendia announced its intention to float on ...
AMSTERDAM, The Netherlands, and IRVINE, California, June 9, 2011 (ots/PRNewswire) -- Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers ...
Amsterdam (ots/PRNewswire) - - Agendia Publishes Prospectus and Sets Indicative IPO Price Range - Not for Release, Distribution or Publication in Whole or in Part, Directly or Indirectly, into or in The United States, Australia, Canada, or Japan This announcement is not a prospectus but an advertisement and nothing herein contains an offering of securities. No one ...
Amsteram and Irvine, California (ots/PRNewswire) - Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it will present results from four completed and one ongoing study, at the Annual Meeting of the American Society of Clinical Oncology (ASCO). Agendia will publish the results of ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- - Recent Study Reveals Substantial Group of Traditionally Miscategorized HER2+ Patients Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van 't Veer, from the Netherlands Cancer Institute, presented the data at the 2008 San Antonio Breast Cancer ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium (SABCS) and ...
HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 18 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint(R), has been included in the updated 2008 guidelines of The Dutch Institute for ...